Shukra Pharmaceuticals has signed a memorandum of understanding with US-based Borns Medical Robotics to introduce and commercialise AI-powered surgical robotic systems in India and select South Asian markets, marking its entry into the medical robotics segment.
Under the MoU, the two companies plan to collaborate on the introduction, promotion and commercialisation of surgical robotics solutions across India, Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to regulatory approvals. The initiative will be executed through Shukra Robotics, a wholly owned subsidiary of Shukra Pharmaceuticals.
The collaboration aims to expand access to robot-assisted minimally invasive surgeries by deploying high-precision, stability-driven surgical robotic platforms, particularly for complex soft-tissue procedures. AI-powered medical robotics systems are increasingly being adopted globally to support surgeons through enhanced visualisation, improved stability and greater standardisation of surgical workflows.
A central focus of the partnership is the integration of artificial intelligence with digital surgery workflows. This is expected to enable more consistent procedural pathways, improve clinical efficiency and reduce variability in surgical outcomes.
The initiative also seeks to strengthen healthcare infrastructure across the region through technology transfer, clinician training programmes and scalable deployment models for medical robotics.
Borns Medical Robotics, a global player in surgical medical robotics, will provide expertise in robotic surgical platforms and AI-enabled technologies. Shukra Pharmaceuticals will leverage its regulatory execution capabilities, established presence in healthcare markets and distribution network across India and South Asia to support adoption and commercialisation.
The MoU is non-binding and reflects the intent of both parties to explore definitive agreements in the future, subject to detailed commercial terms, regulatory clearances and mutual consent.
